Sign in

    Ricki Levitus • Guggenheim Securities

    Ricki Levitus's questions to Myriad Genetics Inc (MYGN) leadership

    Ricki Levitus's questions to Myriad Genetics Inc (MYGN) leadership • Q2 2025

    Question

    Ricki Levitus of Guggenheim Partners, on for Subbu Namdi, asked about the performance of the SneakPeek test and its success in funneling patients to Prequel. She also asked for clarification on what is incrementally new in the strategic plan for the Women's Health and Mental Health businesses.

    Answer

    President and CEO Sam Raha acknowledged that the SneakPeek business has been a 'challenge' and is not a primary area of focus at this time. Regarding the strategic update, he explained that for Women's Health and Mental Health, the key change is a 'deliberate' and disciplined approach to resourcing and investment. The goal is to maintain growth at or above market rates in these areas while prioritizing capital and focus on the higher-growth Cancer Care Continuum pillar.

    Ask Fintool Equity Research AI

    Ricki Levitus's questions to Castle Biosciences Inc (CSTL) leadership

    Ricki Levitus's questions to Castle Biosciences Inc (CSTL) leadership • Q3 2024

    Question

    Ricki Levitus of Guggenheim Securities, on for Subbu Nambi, inquired about the competitive landscape for DecisionDx-Melanoma, specifically asking about the impact of new data and commercial partnerships from competitor SkylineDx.

    Answer

    CEO Derek Maetzold addressed the competitor's recent study, highlighting that its low-risk group had a 7.1% sentinel lymph node positivity rate, which is above the key 5% clinical threshold. He contrasted this with Castle's test, which has been shown to identify low-risk patients below the 5% threshold, suggesting a superior clinical value proposition. He noted minimal field impact from the competitor's partnerships to date.

    Ask Fintool Equity Research AI